Shields Kelsey, Araujo-Castillo Roger V, Theethira Thimmaiah G, Alonso Carolyn D, Kelly Ciaran P
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States.
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Lowry Medical Office Building, Suite GB 110 Francis Street, Boston, MA 02215, United States.
Anaerobe. 2015 Aug;34:59-73. doi: 10.1016/j.anaerobe.2015.04.012. Epub 2015 Apr 27.
Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies.
艰难梭菌感染(CDI)日益普遍,预防和管理具有危险性且颇具挑战性。尽管受到国内外的高度关注,但在过去十年中,原发性和复发性CDI(分别为PCDI和RCDI)的发病率仍迅速上升。主要令人担忧的是RCDI病例的增加,这导致了严重的发病率、死亡率和经济负担。RCDI的管理仍然具有挑战性,因为没有统一有效的治疗方法,对于最佳治疗方案没有坚定的共识,而且关于RCDI特异性治疗选择的可靠数据很少。迫切需要新的治疗策略来快速、准确和有效地识别和治疗患有RCDI或有RCDI风险的患者。在本综述中,我们考虑了与RCDI的流行病学、发病机制和临床表现相关的因素,评估了RCDI的当前管理选择,并探索了新出现的疗法。